Purity ~85% (SDS-PAGE). Three types of arginine methylation exist in mammalian cells: monomethylarginine (MMA), asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA). Type I PRMTs ((CARM1, PRMT1, PRMT2, PRMT3, PRMT6, and PRMT8) catalyze ADMA, while type II PRMTs (e.g. PRMTs 5 and 7) catalyze SDMA. Type II PRMTs are found to be strongly implicated in diseases like cancer. For example, PRMT5 plays a role in the repression of certain tumor suppressor genes such as RB tumor suppressors while PRMT7 overexpression is observed in breast cancer. Source: Recombinant protein corresponding to the complex of human PRMT5 protein (GenBank Accession No. NM_006109), aa2-end, with N-terminal FLAG-Tag, and human MEP50 (GenBank Accession No. NM_024102), aa2-end, with N-terminal His tag, expressed in FreeStyle 293-F cells. Molecular Weight: ~73kD (PRMT5), 37.5kD (MEP50) Assay Conditions: 50ul reaction mix (20mM phosphate buffer, pH 7.4, 20uM S-adenosyl methionine, and 10-100ng methyltransferase PRMT5) add to t